Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Vaccines

Medicago, GSK announce positive data for tobacco-grown COVID-19 vaccine

by Megha Satyanarayana
May 22, 2021 | A version of this story appeared in Volume 99, Issue 19

 

A photo of people tending to tobacco in a greenhouse.
Credit: Medicago
Medicago produces drugs and vaccines in greenhouse-grown tobacco.

Medicago and GlaxoSmithKline are reporting positive data from a Phase 2 clinical trial of a tobacco-grown COVID-19 vaccine. The vaccine, made by Medicago, is coupled with an adjuvant made by GSK. People in the trial developed neutralizing antibody levels 10 times as high as those in people who have had COVID-19, the companies say. Neutralizing antibodies can prevent SARS-CoV-2, the virus that causes COVID-19, from entering cells.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.